- Home
- JXG vs ONCY Comparison
JXG vs ONCY Comparison
Compare JXG & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JXG | ONCY |
|---|---|---|
| Founded | N/A | 1998 |
| Country | China | Canada |
| Employees | 95 | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.2M | 107.3M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | JXG | ONCY |
|---|---|---|
| Price | $11.50 | $0.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 3.4K | ★ 1.5M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,505.00 |
| P/E Ratio | $0.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.77 |
| 52 Week High | $12.00 | $1.51 |
Technical Indicators
Market Signals| Indicator | JXG | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 66.82 | 48.78 |
| Support Level | $3.57 | $0.81 |
| Resistance Level | $11.80 | $1.06 |
| Average True Range (ATR) | 0.71 | 0.07 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 80.00 | 33.81 |
Price Performance
Historical ComparisonAbout JXG JX Luxventure Limited
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products. The Company's operations are located in the PRC and all of the Company's revenue is derived from sales to customers in the PRC region.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.